Skip to main content

Peer Review reports

From: Landiolol, an ultra-short acting beta-1 blocker, for preventing postoperative lung cancer recurrence: study protocol for a phase III, multicenter randomized trial with two parallel groups of patients

Original Submission
4 Jun 2019 Submitted Original manuscript
4 Oct 2019 Reviewed Reviewer Report - Han Zhu
20 Oct 2019 Author responded Author comments - Haruko Yamamoto
Resubmission - Version 2
20 Oct 2019 Submitted Manuscript version 2
15 Nov 2019 Editorially accepted
11 Dec 2019 Article published 10.1186/s13063-019-3904-4

You can find further information about peer review here.

Back to article page